Chinese expert consensus on the diagnosis and treatment of human immunodeficiency virus infection related diffuse large B cell lymphoma（2025）
TL;DR
This paper presents a Chinese expert consensus on diagnosing and treating HIV-related diffuse large B cell lymphoma, aiming to improve clinical practices.
Contribution
The paper introduces a new expert consensus to standardize diagnosis and treatment of HIV+ DLBCL in China.
Findings
HIV+ DLBCL is rare and challenging to diagnose.
Current treatment lacks standardization.
The consensus aims to enhance clinical recognition and management.
Abstract
人类免疫缺陷病毒感染相关弥漫大B细胞淋巴瘤（human immunodeficiency virus infection related diffuse large B cell lymphoma，HIV+ DLBCL）发病率低，诊断具有挑战性，治疗缺乏规范性。为加强我国临床医师对HIV+ DLBCL的认识，提高诊断及治疗水平，中华医学会血液学分会淋巴细胞疾病学组、中国抗癌协会（CACA）淋巴瘤整合康复专委会、中国临床肿瘤学会（CSCO）淋巴瘤专家委员会中西部免疫缺陷相关淋巴瘤诊治协作组（CALL）组织相关专家，讨论并形成本共识。
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.